These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31822495)

  • 1. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control study.
    Flaum N; van Veen EM; Smith O; Amico S; Newman WG; Crosbie EJ; Edmondson R; Smith MJ; Evans DG
    Clin Genet; 2022 Jan; 101(1):48-54. PubMed ID: 34585738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
    De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
    Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the molecular effect of a rare missense mutation in BRIP1 associated with inherited breast cancer.
    Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
    Mol Carcinog; 2019 Jan; 58(1):156-160. PubMed ID: 30230034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
    Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
    Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
    Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
    Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Martín-Morales L; Garre P; Lorca V; Cazorla M; Llovet P; Bando I; García-Barberan V; González-Morales ML; Esteban-Jurado C; de la Hoya M; Castellví-Bel S; Caldés T
    Cancer Prev Res (Phila); 2021 Feb; 14(2):185-194. PubMed ID: 33115781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
    Easton DF; Lesueur F; Decker B; Michailidou K; Li J; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Dennis J; Ahmad J; Thompson ER; Damiola F; Pertesi M; Voegele C; Mebirouk N; Robinot N; Durand G; Forey N; Luben RN; Ahmed S; Aittomäki K; Anton-Culver H; Arndt V; ; Baynes C; Beckman MW; Benitez J; Van Den Berg D; Blot WJ; Bogdanova NV; Bojesen SE; Brenner H; Chang-Claude J; Chia KS; Choi JY; Conroy DM; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Eriksson M; Fasching PA; Figueroa J; Flyger H; Fostira F; García-Closas M; Giles GG; Glendon G; González-Neira A; Guénel P; Haiman CA; Hall P; Hart SN; Hartman M; Hooning MJ; Hsiung CN; Ito H; Jakubowska A; James PA; John EM; Johnson N; Jones M; Kabisch M; Kang D; ; Kosma VM; Kristensen V; Lambrechts D; Li N; ; Lindblom A; Long J; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Meindl A; Mitchell G; Muir K; ; Nevelsteen I; van den Ouweland A; Peterlongo P; Phuah SY; Pylkäs K; Rowley SM; Sangrajrang S; Schmutzler RK; Shen CY; Shu XO; Southey MC; Surowy H; Swerdlow A; Teo SH; Tollenaar RA; Tomlinson I; Torres D; Truong T; Vachon C; Verhoef S; Wong-Brown M; Zheng W; Zheng Y; Nevanlinna H; Scott RJ; Andrulis IL; Wu AH; Hopper JL; Couch FJ; Winqvist R; Burwinkel B; Sawyer EJ; Schmidt MK; Rudolph A; Dörk T; Brauch H; Hamann U; Neuhausen SL; Milne RL; Fletcher O; Pharoah PD; Campbell IG; Dunning AM; Le Calvez-Kelm F; Goldgar DE; Tavtigian SV; Chenevix-Trench G
    J Med Genet; 2016 May; 53(5):298-309. PubMed ID: 26921362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
    Calvo JA; Fritchman B; Hernandez D; Persky NS; Johannessen CM; Piccioni F; Kelch BA; Cantor SB
    Mol Cancer Res; 2021 Jun; 19(6):1015-1025. PubMed ID: 33619228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.